Volume : 10, Issue : 12, December – 2023
Title:
UPDATE ON THE DIAGNOSIS AND MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
Authors :
Ohoud Hassan Balkhair ,Moiyyad Khalid Bashnini , Mdhawi Abdulrazzaq Waro, Ali Ahmed Alramadhan, Anan Ali Baamer, Khalid Mohammed Aljohani, Hussain Obaid Almutairi, Najla Abdullah Alsibyani , Abdulaziz Abbas Alherz, Yazeed Saeed Alsenani, Rania Sami Iraqi, Hadeel Lowthan Alshammari, Muath Abdulaziz Al Ajlan, Abdullah Saeed A Alzaki
Abstract :
Background: systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organ systems, characterized by immune dysregulation and the production of autoantibodies. Pathogenesis involves aberrant activation of programmed cell death (PCD) signaling and accelerated cell death, leading to self-antigens release. SLE manifests with diverse symptoms, ranging from musculoskeletal and gastrointestinal symptoms to neuropsychiatric and cardiovascular complications.
Objective: The present study aims to review the update on the diagnosis and management of systemic lupus erythematosus
Methods: Comprehensive research of the diagnosis and management of SLE. PUBMED and Google scholar search engines were the database used for the search process, and articles were collected from 2013 to 2023. The term used in the search were: Systemic lupus erythematosus (SLE) – manifestation – Diagnostic criteria – treatment.
Conclusion: Accurate diagnosis relies on established criteria like ACR-1997, SLICC-2012, and EULAR/ACR-2019, incorporating clinical and immunological features. Various diagnostic methods, such as immunoassays and multi-omics analysis, contribute to precise diagnosis, with ongoing evaluation of criteria in juvenile SLE. SLE management involves a multidisciplinary approach, combining conventional therapies, targeted biological agents, and adjuvant treatments. The focus remains on improving treatment response, enhancing quality of life, and minimizing side effects. Ongoing research endeavors seek to deepen our understanding of SLE and develop novel therapeutic strategies for this challenging autoimmune disorder.
Keywords: Systemic lupus erythematosus (SLE) – manifestation – Diagnostic criteria – treatment.
.
Cite This Article:
Please cite this article in press Ohoud Hasan Balkhair et al., Update On The Diagnosis And Management Of Systemic Lupus Erythematosus, Indo Am. J. P. Sci, 2023; 10 (12).
Number of Downloads : 10
References:
1. Trivedi J, Rana T, Ani S, Rathva P, Patel M: Let’s know systemic lupus erythematosus. Journal of Clinical Images and Medical Case Reports. 2023, 4:2345.
2. Lam NV, Brown JA, Sharma R: Systemic Lupus Erythematosus: Diagnosis and Treatment. Am Fam Physician. 2023, 107:383-395.
3. Tanaka Y: Systemic lupus erythematosus. Best Practice & Research Clinical Rheumatology. 2022, 36:101814. https://doi.org/10.1016/j.berh.2022.101814
4. Nasonov E, Soloviev S, Arshinov V: Systemic lupus erythematosus: history and modernity. Rheumatology Science and Practice. 2022, 60:397-412. 10.47360/1995-4484-2022-397-412
5. Akhtari M, Farhadi E, Mahmoudi M: Chapter 14 – Immunopathogenesis of systemic lupus erythematosus. Translational Autoimmunity. Rezaei N (ed): Academic Press; 2023. 265-292. https://doi.org/10.1016/B978-0-323-85831-1.00014-0
6. Xu Y, Li P, Li K, et al.: Pathological mechanisms and crosstalk among different forms of cell death in systemic lupus erythematosus. Journal of Autoimmunity. 2022, 132:102890. https://doi.org/10.1016/j.jaut.2022.102890
7. Escoda T, Jourde-Chiche N, Granel B, Cornec D, Chiche L: Complex relationships between inflammatory manifestations/type 1 and type 2 symptoms in systemic lupus erythematosus: A narrative literature review. Lupus. 2023, 32:942-951. 10.1177/09612033231179773
8. Hafeez MH, Safdar W, Arshad A, et al.: Systemic Lupus Erythematosus and its major organ complications: a narrative review on available literature. Liaquat National Journal of Primary Care. 2022. 10.37184/lnjpc.2707-3521.5.12
9. Kamen DL, Birt J, Hadi M, et al.: POS0744 SYSTEMIC LUPUS ERYTHEMATOSUS WITH ACTIVE MUSCULOSKELETAL SYMPTOMS: PATIENT REPORTED SYMPTOM IMPACT, TREATMENT PATTERNS AND SATISFACTION WITH CURRENT THERAPY OPTIONS. Annals of the Rheumatic Diseases. 2022, 81:656.652-657. 10.1136/annrheumdis-2022-eular.2095
10. Ronen JA, Mekala A, Wiechmann C, Mungara S: A Flare-up of Systemic Lupus Erythematosus with Unusual Enteric Predominance . Cureus. 2020. 10.7759/cureus.7068
11. Mv P, Maikap D, Padhan P: Parkinsonism as the presenting manifestation of lupus: A case-based review. Lupus. 2023, 32:1001-1007. 10.1177/09612033231181636
12. Gil Velez RJ, Mendez Diaz L, Madroñal García I: AB0685 DESCRIPTIVE STUDY OF A COHORT OF PATIENTS WITH NEUROPSYCHIATRIC MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS IN A TERTIARY HOSPITAL. Volume 82. Suppl 1 edition. BMJ Publishing Group Ltd and European League Against Rheumatism:1546.1541-1546.
13. Bryam Esteban Coello G, Diana Carolina Martínez P, José Javier Ordoñez C, et al.: BRIEF REVIEW ABOUT NEUROLOGICAL, HEMATOLOGICAL, GASTROINTESTINAL, CARDIOVASCULAR AND PULMONAR MANIFESTATIONS OF SYSTEMIC ERYTHEMATOSUS LUPUS. EPRA International Journal of Multidisciplinary Research (IJMR). 2023:161-164. 10.36713/epra12235
14. Kedia N, Theillac V, Paez-Escamilla M, et al.: The full range of ophthalmological clinical manifestations in systemic lupus erythematosus. Frontiers in Ophthalmology. 2023, 2. 10.3389/fopht.2022.1055766
15. Sullivan MM, Salem F, Albadri S, Berianu F: Clinical Images: Dacryoadenitis as the herald symptom for systemic lupus erythematosus. ACR Open Rheumatology. 2023, 5:436-436. 10.1002/acr2.11553
16. Murugan SB, Somanath A: Commentary: Systemic lupus erythematosus retinopathy: Eye or multisystem involvement? Indian Journal of Ophthalmology. 2023, 71.
17. Reshetnyak TM, Lisitsyna TA, Cheldieva FA, et al.: Comparative assessment of sensitivity and specificity of three variants of classification criteria for systemic lupus erythematosus in a cohort of Russian patients. TA. 2023, 95:410-417. 10.26442/00403660.2023.05.202201
18. Said MSM, Ee SC, Mustafa R: AB0684 RETROSPECTIVE STUDY ON SENSITIVITY AND SPECIFICITY OF VARIOUS CLASSIFICATION CRITERIA IN EARLY DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS AND LINK TO DISEASE OUTCOMES. Annals of the Rheumatic Diseases. 2023, 82:1545-1545. 10.1136/annrheumdis-2023-eular.2511
19. Determination of specific autoantibodies in patients with systemic lupus erythematosus by Line immunoassay, ELISA and CLIF. Asian Pacific Journal of Allergy and Immunology. 2023. 10.12932/ap-301019-0681
20. Wang W, Wang Y, Guo F, et al.: Development and validation of a serum multi-omics based diagnostic model for systemic lupus erythematosus. Research Square Platform LLC; 2022.
21. Khalifah MJ, Almansouri O, Mowallad A, et al.: Comparison of Indirect Immunofluorescence and Enzyme Immunoassay for the Detection of Antinuclear Antibodies. Cureus. 2022. 10.7759/cureus.31049
22. Infantino M, Palterer B, Previtali G, et al.: Comparison of current methods for anti-dsDNA antibody detection and reshaping diagnostic strategies. Scandinavian Journal of Immunology. 2022, 96:e13220. https://doi.org/10.1111/sji.13220
23. Katarzyna P-B, Wiktor S, Ewa D, Piotr L: Current treatment of systemic lupus erythematosus: a clinician’s perspective. Rheumatology International. 2023, 43:1395-1407. 10.1007/s00296-023-05306-5
24. Athanassiou P, Athanassiou L: Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus. MDPI AG; 2023.
25. El Hussein MT, Wong C: Systemic lupus erythematosus: An approach to pharmacologic interventions. The Nurse Practitioner. 2023, 48.
26. Puaratanaarunkon T, Kerr SJ, Rerknimitr P: Efficacy of antimalarial agents to prevent the progression of discoid lupus erythematosus to systemic lupus erythematosus: A retrospective cross-sectional study. Asian Pac J Allergy Immunol. 2022. 10.12932/ap-290122-1321
27. Walhelm T, Wirestam L, Parodis I, Sjöwall C: PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry. Lupus Foundation of America.
28. Enríquez-Merayo E, Cuadrado MJ: 2023 Steroids in Lupus: Enemies or Allies. Journal of Clinical Medicine 12.
29. Katz P, Pedro S, Choi J, Michaud K: AB0342 ASSOCIATION OF GLUCOCORTICOID USE WITH HEALTHCARE UTILIZATION AMONG PERSONS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Volume 82. Suppl 1 edition. BMJ Publishing Group Ltd and European League Against Rheumatism:1354.1351-1355.
30. Blachut D, Przywara-Chowaniec B, Harpula J, Tomasik A, Nowalany-Kozielska E, Morawiec B: The effects of glucocorticoid treatment on cardiovascular system in patients with systemic lupus erythematosus. Archives of Rheumatology. 2022, 37:495-503. 10.46497/archrheumatol.2022.9255
31. Wise L, Stohl W: Chapter 39 – Immunosuppressive therapy in SLE. Lahita’s Systemic Lupus Erythematosus (Sixth Edition). Lahita RG, Costenbader KH, Bucala R, Manzi S, Khamashta MA (eds): Academic Press, San Diego; 2021. 623-659. https://doi.org/10.1016/B978-0-12-820583-9.00044-0
32. Athanassiou P, Athanassiou L, Kostoglou-Athanassiou I: Novel Therapeutic Interventions in Systemic Lupus Erythematosus. IntechOpen; 2021. 10.5772/intechopen.97168
33. Mustafayeva L, Durucan I, Ayla A, Ugurlu S: PO.3.68 Systemic lupus erythematosus-related intestinal pseudo-obstruction treated with immunosuppressants. Lupus Foundation of America.
34. Park S-H: Biologic therapies for the treatment of systemic lupus erythematosus. Journal of the Korean Medical Association. 2021, 64:109-115. 10.5124/jkma.2021.64.2.109
35. Chavarría-Tapia A, Fernández-Corella A, Marenco-Acosta H, Zhou YS, Ugalde-Zumbado M, Mora-Román JJ: Anticuerpos monoclonales y el tratamiento del lupus eritematoso sistémico. . Tecnología en Marcha. 2021, 34:25-39. doi: 10.18845/TM.V34I1.4654
36. Nikolopoulos D, Parodis I: Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition. Frontiers in Medicine. 2023, 10. 10.3389/fmed.2023.1217147
37. R H, X H, Y Y, J L: Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus. Journal of Inflammation Research. 2023, 16:1471-1478. doi: 10.2147/JIR.S397639
38. Cajamarca-Barón J, Buitrago-Bohórquez J, Mendoza Orozco JE, et al.: Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature. Autoimmunity Reviews. 2022, 21:103182. https://doi.org/10.1016/j.autrev.2022.103182
39. Vida AC, Sala I, Fernandes J, Castro A, Freitas C, Lobato L: #6167 THERAPEUTIC PLASMA EXCHANGE AS A TOOL IN THE TREATMENT OF NEUROLOGICAL DISEASES: A SINGLE CENTER EXPERIENCE. Nephrology Dialysis Transplantation. 2023, 38:gfad063c_6167. 10.1093/ndt/gfad063c_6167
40. Lee J-H, Jeon H-W, Moon S-J, Lee M-Y: Treatment of Various Ocular Manifestation of Systemic Lupus Erythematosus with Therapeutic Plasma Exchange. Journal of Clinical Medicine. 2022, 11:6632. 10.3390/jcm11226632